DBV Technologies (NASDAQ:DBVT) Given New $7.00 Price Target at HC Wainwright

DBV Technologies (NASDAQ:DBVT) had its price target upped by HC Wainwright from $5.00 to $7.00 in a research report report published on Thursday, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for DBV Technologies’ FY2024 earnings at ($1.41) EPS, FY2027 earnings at ($1.06) EPS and FY2028 earnings at ($0.50) EPS.

A number of other brokerages have also weighed in on DBVT. JMP Securities reissued a “market outperform” rating and issued a $5.00 price target on shares of DBV Technologies in a report on Tuesday, September 24th. StockNews.com assumed coverage on shares of DBV Technologies in a report on Monday, October 21st. They issued a “hold” rating for the company.

DBV Technologies Trading Up 3.5 %

NASDAQ:DBVT opened at $0.87 on Thursday. DBV Technologies has a 1 year low of $0.50 and a 1 year high of $2.28. The firm has a 50 day moving average of $0.77 and a 200-day moving average of $0.95. The stock has a market capitalization of $83.61 million, a P/E ratio of -1.03 and a beta of 0.67.

DBV Technologies (NASDAQ:DBVT) last posted its earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. The firm had revenue of $1.16 million during the quarter, compared to the consensus estimate of $1.42 million. During the same quarter last year, the firm posted ($0.26) EPS. As a group, analysts forecast that DBV Technologies will post -1.43 EPS for the current fiscal year.

Institutional Trading of DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. boosted its holdings in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the first quarter, according to its most recent filing with the SEC. The firm owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the period. DBV Technologies accounts for 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th largest position. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 as of its most recent SEC filing. 71.74% of the stock is owned by institutional investors and hedge funds.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.